Inhibrx
- Founded: 2010
- Location: La Jolla, CA
- Employee range: 50 - 200
- Clinical stage: Clin2
- Therapy area: Chondrosarcoma
- Drug types: ONC, GEN
- Lead product: INBRX-109
- Product link: https://inhibrx.com/pipeline/
- Funding: $200M stock Aug 2023; $137M IPO Aug 2020; $40M May 2019
- Investors: Viking Global Investors
inhibrx.com linkedin.com job board
Short description:
Antibodies, Fusion Proteins
Drug notes:
Also Clin1 multiple cancers; INBRX-101 Clin1 alpha-1 antitrypsin deficiency (FT); INBRX-106 Clin1 multiple cancers; INBRX-105 Clin1 multiple cancers; INBRX-121 RD/Clin0 oncology
Long description:
Inhibrx is a clinical-stage biotechnology company focused on helping people with life-threatening diseases. Using their protein-engineering expertise and proprietary single-domain antibody platform, Inhibrx has developed a unique and varied pipeline of novel therapeutic candidates. The platform enables the company to address complex target biology where other biologic approaches have previously failed as Inhibrix has the ability to create therapeutic candidates with defined valencies and specificities. Currently, Inhibrx has four programs all undergoing testing in clinical trials, three of which are for the treatment of cancer.
© 2024 Work In Biotech LLC
Personal dataTerms of ServicePrivacy PolicyContact: recruit@workinbiotech.com
Personal dataTerms of ServicePrivacy PolicyContact: recruit@workinbiotech.com